Holding(s) in Company
Novo Holdings A/S has notified Oxford Nanopore Technologies plc of a change in its major holding, with its voting rights decreasing from 4.998888% to 0.000000% as of September 4, 2026. This notification signifies an acquisition or disposal of voting rights, and Novo Holdings A/S, the holding company of the Novo Group wholly owned by the Novo Nordisk Foundation, no longer holds any direct or indirect voting rights or financial instruments in the company.
Select text to share a quote on X · sign in to keep highlights & notes in your ONT notes
Issuer Details
ISIN
GB00BP6S8Z30
Issuer Name
OXFORD NANOPORE TECHNOLOGIES PLC
UK or Non-UK Issuer
UK
Reason for Notification
An acquisition or disposal of voting rights
Details of person subject to the notification obligation
Name
Novo Holdings A/S
City of registered office (if applicable)
Hellerup
Country of registered office (if applicable)
Denmark
Details of the shareholder
City of registered office (if applicable)
Country of registered office (if applicable)
Date on which the threshold was crossed or reached
04-Sep-2026
Date on which Issuer notified
04-Sep-2026
- Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer | |
|---|---|---|---|---|
| Resulting situation on the date on which threshold was crossed or reached | 0.000000 | 0.000000 | 0.000000 | 0 |
| Position of previous notification (if applicable) | 4.998888 | 0.000000 | 4.998888 | |
| 8A. Voting rights attached to shares | ||||
| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
| GB00BP6S8Z30 | 0 | 0 | 0.000000 | 0.000000 |
| Sub Total 8.A | 0 | 0.000000% | ||
| 8B1. Financial Instruments according to (DTR5.3.1R.(1) (a)) | ||||
| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
Sub Total 8.B1
- Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
Sub Total 8.B2
- Information in relation to the person subject to the notification obligation
| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
If date does not apply, explain below
Additional Information
The qualifying instruments are held by Novo Holdings A/S, the holding company in the Novo Group. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation.
Date of Completion
04-Sep-2026
Place Of Completion
London, United Kingdom
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.